Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.70 |
| ▸ | FAP | Q12884 | 9/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.65 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.65 |
| ▸ | HRH2 | P25021 | 1/20 | 0.65 |
| ▸ | MC4R | P32245 | 1/20 | 0.65 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.65 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.65 |
| ▸ | GHSR | Q92847 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17036591 | 0.90 | DPP4 (0.72) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL3919837 | 0.89 | DPP4 (0.70) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL29350672 | 0.89 | DPP4 (0.70) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL18343936 | 0.89 | DPP4 (0.70) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL12862005 | 0.89 | DPP4 (0.70) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL16416909 | 0.87 | DPP4 (0.68) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL29456463 | 0.84 | DPP4 (0.64) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL20296912 | 0.84 | DPP4 (0.64) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL15083818 | 0.84 | DPP4 (0.85) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL15840849 | 0.83 | DPP4 (0.70) | DPP4FAPCHRM1POU2F2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023156675-A1 | PROCESS FOR PURIFICATION OF LINAGLIPTIN | KRKA, D.D., NOVO MESTO (SI) | 2023-08-24 | — | — | WO | disclosed |
| EP-3974431-A1 | PROCESS FOR THE PREPARATION OF A XANTHINE-BASED COMPOUND | Boehringer Ingelheim International GmbH (DE) | 2022-03-30 | — | — | EP | disclosed |
| US-10253026-B2 | Process for the preparation of (r)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1h-purine-2,6-dione | Boenringer Ingelheim International GmbH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-10253026-B2 | Process for the preparation of (r)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1h-purine-2,6-dione | Boenringer Ingelheim International GmbH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-20180179207-A1 | PROCESS FOR THE PREPARATION OF A XANTHINE-BASED COMPOUND | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180179207-A1 | PROCESS FOR THE PREPARATION OF A XANTHINE-BASED COMPOUND | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180179207-A1 | PROCESS FOR THE PREPARATION OF A XANTHINE-BASED COMPOUND | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| EP-3313841-A1 | PROCESS FOR THE PREPARATION OF A XANTHINE-BASED COMPOUND | Boehringer Ingelheim International GmbH (DE) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016207364-A1 | PROCESS FOR THE PREPARATION OF A XANTHINE-BASED COMPOUND | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179207-A1 | PROCESS FOR THE PREPARATION OF A XANTHINE-BASED COMPOUND | XDH, HPRT1, NUDT1 | DPP4 363/4885FAP 1240/4885CHRM1 1860/4885 |
| US-10253026-B2 | Process for the preparation of (r)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1h-purine-2,6-dione | XDH, DHPS, UMPS | DPP4 1636/4885FAP 3112/4885CHRM1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.